To The Moon

$Harrow Health Inc(HROW)$ +12% 🟢

The company just attended the Piper Sandler Healthcare Conference and got an overwhelmingly positive response. Institutional investors are finally realising $HROW potential.

1) Melt 300 will be huge.

This is Harrow's recently acquired non-opioid sedative that's highly effective for eye care procedures. Already, just this use case is massive. However, Harrow is planning to partner with other pharmaceutical companies to expand to new verticals, such as dental, plastic surgery, dermatology, and anxiety sedation.

2) They are also seeking partners to potentially sell Melt internationally.

3) VEVYE, their potential blockbuster dry eye disease drug, has doubled market share in just 2 quarters. Recently, it received a preferred treatment status for this condition with US's largest pharmacy benefit manager. This will increase availability. Furthermore, the company is doubling its VEVYE sales team to capitalize on this.

4) IHEEZO potential is also massive.

This is an ocular aesthetic that is more effective and has fewer side effects than comparable treatments. The company aims for a 10% market share, which would help it achieve the 2027 goal of $75M in revenues in Q4 2027. For context, this drug had sales of $68M in the last 12 months. So by Q4 2027, they aim to have higher quarterly sales than in LTM.

5) The biosimilar potential for eye degeneration treatments is massive as well.

$HROW assesses that 1% market share is worth $80M, if they can get a 3-4% market share, this would be $240-$320M in revenues in 2027-2028. Reminder, LTM revenues of the whole company are $250M, so this one drug category alone could be equal to the current revenue of the whole company in a few years.

6) In terms of future M&A $HROW said they are looking to buy a dollar for a dime. They are focused on scaling the Melt acquisition and the current portfolio. This should be enough to have a "very large market cap company."

BULLISH HROW

For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.

Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.

Click to access the activity

Other helpful links:

• 💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉

• How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.